A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients

Basit Öğe Kaydı
dc.authoridPoturoglu, Sule/0000-0002-2722-9636
dc.authoridATES, YUKSEL/0000-0001-6800-3708
dc.authorwosidKaymakoglu, Sabahattin/AAT-2362-2020
dc.authorwosidPoturoglu, Sule/AAL-4925-2021
dc.authorwosidPoturoglu, Sule/AAL-2993-2020
dc.authorwosidOnuk, Mehmet Derya/HJA-2650-2022
dc.authorwosidEllidokuz, Ender/P-1554-2019
dc.contributor.authorAvsar, Erol
dc.contributor.authorTiftikci, Arzu
dc.contributor.authorPoturoglu, Sule
dc.contributor.authorErzin, Yusuf
dc.contributor.authorKocakaya, Ozan
dc.contributor.authorDincer, Dinc
dc.contributor.authorYildirim, Bulut
dc.date.accessioned2024-08-04T20:37:53Z
dc.date.available2024-08-04T20:37:53Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground/aims: Proton-pump inhibitor- and ranitidine bismuth citrate-based triple regimens are the two recommended first-line treatments for the eradication of Helicobacter pylori. We aimed to compare the effectiveness and tolerability of these two treatments in a prospective, multi-centric, randomized study. Materials and Methods: Patients with dyspeptic complaints were recruited from 15 study centers. Presence of Helicobacter pylori was investigated by both histology and rapid urease test. The patients were randomized to either ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=149) or lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=130) treatment arm for 14 days. Adverse events have been recorded during the treatment phase. A C-13 urea breath test was performed 6 weeks after termination of treatment to assess the efficacy of the therapy. Eradication rate was calculated by intention-to-treat and per-protocol analysis. Results: Two hundred seventy-nine patients (123 male, 156 female) were eligible for randomization. In per-protocol analysis (n=247), Helicobacter pylori was eradicated with ranitidine bismuth citrate- and lansoprazole-based regimens in 74,6% and 69,2% of cases, respectively (p>0,05). Intention-to-treat analysis (n=279) revealed that eradication rates were 65,1% and 63,6% in ranitidine bismuth citrate- and in lansoprazole-based regimens, respectively (p>0,05). Both regimes were well-tolerated, and no serious adverse event was observed during the study. Conclusion: Ranitidine bismuth citrate-based regimen is at least as effective and tolerable as the classical proton-pump inhibitor-based regimen, but none of the therapies could achieve the recommendable eradication rate.en_US
dc.identifier.doi10.4318/tjg.2013.0509
dc.identifier.endpage321en_US
dc.identifier.issn1300-4948
dc.identifier.issue4en_US
dc.identifier.pmid24254262en_US
dc.identifier.scopus2-s2.0-84886414261en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage316en_US
dc.identifier.urihttps://doi.org/10.4318/tjg.2013.0509
dc.identifier.urihttps://hdl.handle.net/11616/96250
dc.identifier.volume24en_US
dc.identifier.wosWOS:000326481900003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Soc Gastroenterologyen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRanitidine bismuth citrateen_US
dc.subjectlansoprazoleen_US
dc.subjectHelicobacter pylorien_US
dc.subjecteradicationen_US
dc.titleA multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu